The magic isn't over for Eli Lilly (NYSE: LLY). Though the pharmaceutical giant isn't performing as well in the second half of the year as it did in the first, it still has plenty of fuel for growth.

One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company could benefit from the government coverage of its weight loss medicines.

NEW DELHI: Eli Lilly, the US pharmaceutical giant that gained widespread attention globally with its weight-loss treatments, plans to launch its blockbuster drug - Tirzepatide - in India in 2025.

Eli Lilly and Novo Nordisk dominate the market for weight loss drugs, and demand for their products has surpassed supply in recent times. Lilly’s weight loss portfolio has already delivered ...

ELI LILLY AND COMPANY WILL BE EXPANDING ITS FACILITY JUST WEST OF I-94 IN PLEASANT PRAIRIE. 12 NEWS IS HANNAH HILYARD IS LIVE THERE TONIGHT. AND HANNAH. THE COMPANY CALLS IT THEIR MOST AMBITIOUS ...

Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:LLY) to enhance patient access to Zepbound (tirzepatide) single-dose vials for obesity treatment. Through LillyDirect, Ro will provide ...

Eli Lilly LLY recently announced its plans to spend $3 billion to expand the manufacturing facility in Wisconsin that was acquired earlier this year from Nexus Pharmaceuticals. Management expects ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $994.00. The company’s shares closed last ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly. In a head-to-head comparison of the two GLP-1 drugs ...

With a positive phase 3 trial in chronic lymphocytic leukemia (CLL), Eli Lilly hopes to convert Jaypirca’s unique accelerated approval—which allows the BTK inhibitor to be used following anoth ...